Zacks Investment Research Upgrades Stemline Therapeutics (STML) to “Hold”

Share on StockTwits

Stemline Therapeutics (NASDAQ:STML) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Tuesday.

According to Zacks, “Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric and adult high-grade gliomas. Stemline Therapeutics, Inc. is based in New York. “

A number of other research firms also recently commented on STML. Piper Jaffray Companies reaffirmed an “overweight” rating on shares of Stemline Therapeutics in a research note on Wednesday, February 6th. HC Wainwright set a $38.00 price objective on shares of Stemline Therapeutics and gave the company a “buy” rating in a research note on Wednesday, November 21st. Roth Capital set a $33.00 price objective on shares of Stemline Therapeutics and gave the company a “buy” rating in a research note on Wednesday, November 14th. ValuEngine raised shares of Stemline Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, November 23rd. Finally, BidaskClub downgraded shares of Stemline Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, November 29th. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Stemline Therapeutics has a consensus rating of “Buy” and an average price target of $25.40.

Stemline Therapeutics stock opened at $11.60 on Tuesday. Stemline Therapeutics has a 52 week low of $7.82 and a 52 week high of $20.55. The stock has a market capitalization of $380.66 million, a P/E ratio of -3.95 and a beta of 1.12.

In related news, COO Kenneth Hoberman sold 10,557 shares of the stock in a transaction that occurred on Monday, February 25th. The shares were sold at an average price of $12.05, for a total transaction of $127,211.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider David Gionco sold 8,563 shares of the stock in a transaction that occurred on Monday, February 25th. The stock was sold at an average price of $12.03, for a total transaction of $103,012.89. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 89,704 shares of company stock valued at $1,018,043. Corporate insiders own 14.80% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Polar Capital LLP increased its position in Stemline Therapeutics by 12.1% during the 4th quarter. Polar Capital LLP now owns 2,302,666 shares of the biopharmaceutical company’s stock worth $21,875,000 after purchasing an additional 248,616 shares in the last quarter. BlackRock Inc. increased its position in Stemline Therapeutics by 4.9% during the 4th quarter. BlackRock Inc. now owns 2,065,239 shares of the biopharmaceutical company’s stock worth $19,618,000 after purchasing an additional 95,747 shares in the last quarter. Vanguard Group Inc increased its position in Stemline Therapeutics by 1.5% during the 3rd quarter. Vanguard Group Inc now owns 1,278,029 shares of the biopharmaceutical company’s stock worth $21,215,000 after purchasing an additional 18,487 shares in the last quarter. Vanguard Group Inc. increased its position in Stemline Therapeutics by 1.5% during the 3rd quarter. Vanguard Group Inc. now owns 1,278,029 shares of the biopharmaceutical company’s stock worth $21,215,000 after purchasing an additional 18,487 shares in the last quarter. Finally, Nexthera Capital LP increased its position in Stemline Therapeutics by 4.0% during the 3rd quarter. Nexthera Capital LP now owns 582,070 shares of the biopharmaceutical company’s stock worth $9,662,000 after purchasing an additional 22,553 shares in the last quarter. 66.28% of the stock is owned by hedge funds and other institutional investors.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma.

Read More: Capital Gains

Get a free copy of the Zacks research report on Stemline Therapeutics (STML)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

B. Riley Lowers Spark Energy  Price Target to $10.00
B. Riley Lowers Spark Energy Price Target to $10.00
Zacks Investment Research Upgrades Stemline Therapeutics  to “Hold”
Zacks Investment Research Upgrades Stemline Therapeutics to “Hold”
Automatic Data Processing  Receiving Somewhat Critical Press Coverage, Study Finds
Automatic Data Processing Receiving Somewhat Critical Press Coverage, Study Finds
El Paso Electric  Raised to “Hold” at Williams Capital
El Paso Electric Raised to “Hold” at Williams Capital
ALLCOIN Price Hits $0.0000
ALLCOIN Price Hits $0.0000
Q4 2019 EPS Estimates for AMN Healthcare Services, Inc. Reduced by Analyst
Q4 2019 EPS Estimates for AMN Healthcare Services, Inc. Reduced by Analyst


Leave a Reply

© 2006-2019 Ticker Report